Regadenoson Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 0.4 mg/5 mL
Reference Brands: Lexiscan (USA)
Category:
Critical Care
Regadenoson is available in injection (prefilled syringe)
and strengths such as 0.4 mg/5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Regadenoson is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Regadenoson can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Regadenoson is a selective A2A adenosine receptor agonist used as a pharmacologic stress agent in myocardial perfusion imaging (MPI) for the evaluation of coronary artery disease. It is primarily indicated for patients who are unable to perform adequate exercise-based stress testing. By selectively activating the A2A adenosine receptors in coronary arteries, Regadenoson induces rapid and controlled coronary vasodilation, leading to increased coronary blood flow and enhanced myocardial perfusion for accurate radionuclide imaging.
Compared to non-selective agents such as adenosine, Regadenoson offers improved tolerability due to its high selectivity for the A2A receptor. It has minimal activity at A1 receptors and negligible affinity for A2B and A3 receptors, which significantly reduces the incidence of undesirable side effects like bronchoconstriction, atrioventricular block, and severe hypotension. Regadenoson also has a longer half-life than adenosine, allowing sustained hyperemia with a single intravenous bolus administration.
Because of its predictable pharmacologic profile, ease of administration, and favorable safety characteristics, Regadenoson has become a preferred agent in nuclear cardiology for pharmacologic stress testing and myocardial perfusion imaging in both clinical and diagnostic settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing